Diagnosis & Differentiation
PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma
Cancer Science 2025 June 24 [Link] Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii Abstract Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis. We have previously discovered that oxytocin…
Read MoreFibulin-3 in plasma and pleural effusion as a biomarker of mesothelioma
Radiology and Oncology 2025 June 16 [Link] Katja Adamic, Mateja Marc Malovrh, Urska Bidovec Stojkovic, Ales Rozman Abstract Background: Malignant pleural mesothelioma (MPM) is a global health concern linked to asbestos exposure. In Slovenia, regions with high asbestos exposure rates make MPM a significant public health issue. Although thoracoscopic biopsy is the gold standard for…
Read MoreIdentification of a novel prognostic gene signature in pleural mesothelioma: a study based on The Cancer Genome Atlas database and experimental validation
Translational Cancer Research 2025 May 30 [Link] Xinmeng Wang, Yongqin Yang, Wenzhong Yang, Xi Yang, Jinsong Li, Yaru Lin, Zhengliang Li, Jiangyan Li, Wei Xiong Abstract Background: Early detection and prognostic prediction are crucial in improving the survival of patients with pleural mesothelioma (PM). Therefore, this study aimed to develop a gene prognostic risk model…
Read MoreExpression of Heart Development Protein With EGF-Like Domains 1 (HEG1) Decorated With Low-Sulfated Keratan Sulfate in Human Malignant Pleural Mesothelioma
Pathology International 2025 June 17 [Link] Koki Nakashima, Hitomi Hoshino, Zui Zhang, Tomoya O Akama, Nobuyuki Kondo, Seiki Hasegawa, Yoshitaka Sekido, Mana Fukushima, Tamotsu Ishizuka, Motohiro Kobayashi Abstract The glycoform of heart development protein with EGF-like domains 1 (HEG1) recognized by the SKM9-2 monoclonal antibody is a useful diagnostic marker for malignant pleural mesothelioma (MPM).…
Read MoreMolecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities
Diagnostics (Basel) 2025 May 24 [Link] Teodora Zahiu, Carmen Mihaela Mihu, Bianca A Bosca, Mariana Mărginean, Lavinia Patricia Mocan, Roxana-Adelina Ștefan, Rada Teodora Suflețel, Carina Mihu, Carmen Stanca Melincovici Abstract Pleural mesothelioma (PM) is a rare disease, which is going to be a global medical concern in the 21st century, because of its aggressiveness, late…
Read MoreVolatile organic compounds in exhaled human breath for the diagnosis of malignant pleural mesothelioma: a meta-analysis
Frontiers in Oncology 2025 May 28 [Link] Tingting Zhao, Xiao Hu , Minghua Peng, Wei Wei, Ninghua Fu, Chen Chen, Zhenguang Chen Abstract Objective: Malignant pleural mesothelioma (MPM) is a relatively rare thoracic tumor with a high mortality rate, making early diagnosis and treatment challenging. The present study evaluated the utility of exhaled volatile organic…
Read MoreExploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells
Medical Oncology 2025 June 10 [Link] Dayk Muratoglu, Gulseren Turhal, Busra Demirkan, Izel Nermin Baslilar Nimet Sule Yuncu, Asuman Demiroglu-Zergeroglu Abstract Malignant Pleural Mesothelioma (MPM) is the most prevalent type of Mesothelioma and currently has no effective treatment options. This underscores the urgent need to explore new therapeutic agents and innovative strategies. Phenolic acids are…
Read MoreImmune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma
Frontiers in Pharmacology 2025 May 23 [Link] Lin Shi, Dongqi Yuan, Fuyi Zhu, Yuchao He, Ran Zuo, Liwei Chen, Yi Luo, Yu Wang, Dingzhi Huang, Peng Chen, Hua Guo Abstract Background: Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure. Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic…
Read MoreCisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses
Pathology, Research, and Practice 2025 July [Link] Zhenghua Zhang, Wenjun Gao, Feng Yuan, Yubin Hu, Xiaoyu Tuo, Liangping Luo, Xiaonan Tang, Shasha Shen, Yang Tian, Dan Han Abstract Objective: Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy. We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics…
Read MoreSarcomatoid mesothelioma vs. myogenic sarcoma: a strong case for diagnostic electron microscopy: a case report
Ultrastructural Pathology 2025 May 25 [Link] Nadine H Oury, Katherine Killian D O, Tim D Oury Abstract Mesothelioma is often considered a difficult diagnosis due to its rarity, the wide variety of histological patterns and the propensity of metastasis from cancers of unknown origin to serosal surfaces. The advent of numerous new immunochemical markers has…
Read More
Skip to content